Loading...

SCN

SCN

SCINAI IMMUNOTHERAPEUTICS LTD

(SCNI)

2024 6-K

Annual Meeting Notice

12 May '26

Acquisition Report

8 May '26

Private Placement Details

27 Apr '26

Corporate Acquisition Update

23 Mar '26

Nasdaq Notification

19 Mar '26

Innovation Support Boost

25 Feb '26

Acquisition Completed

17 Feb '26

Annual Meeting Results

23 Dec '25

2025 Results Report

2 Dec '25

Annual Meeting Notice

13 Nov '25

Board Resignations

13 Nov '25

Funding Award Announcement

6 Oct '25

Grant Application Update

22 Sep '25

Equity Purchase Agreement

11 Sep '25

Business Update Provided

2 Sep '25

Funding Announcement

12 Jun '25

Government Clearance

5 Jun '25

Financial Results Announcement

2 Jun '25

Acquisition Announcement

27 Mar '25

License Agreement Termination

24 Mar '25

Equity Purchase Agreement

5 Mar '25

Equity Purchase Agreement

4 Mar '25

Q3 2024 Results

25 Nov '24

Annual Meeting Results

22 Nov '24

Annual Meeting Notice

15 Oct '24

License Agreement

26 Sep '24

Financial Statements Update

9 Sep '24

Compliance Regained

29 Aug '24

Debt Restructuring

21 Aug '24

Equity Investment Agreement

20 Aug '24

Financial Update

15 Aug '24

Loan Restructuring Agreement

13 Aug '24

Shareholder Meeting Results

12 Aug '24

Correction Notice Issued

7 Aug '24

Shareholder Notice

5 Aug '24

Q1 2024 Results

15 Jul '24

Positive Trial Results

15 Jul '24

Shareholder Meeting Notice

8 Jul '24

Investment Update

8 Jul '24

Nasdaq Compliance Extended

8 Jul '24

Company Update

14 Jun '24

Investment Conversion

13 Jun '24

Compliance Regained

13 Jun '24

Compliance Update

28 May '24

Financial Report Issued

15 May '24

Nasdaq Delisting Notice

7 May '24

Presentation Update

25 Apr '24

Company Update

16 Apr '24

New Business Updates

18 Jan '24

Company Update

9 Jan '24

Warrant Exercise Completion

4 Jan '24

Warrant Exercise Agreement

2 Jan '24

Warrant Exercise Announcement

2 Jan '24

License Agreement with Max-...

8 Jun '23

Resignation of Director

11 May '23

Delisting

4 May '23

Disclosure of Investor Pres...

4 May '23

External Links:

SEC

On September 26, 2024, Scinai Immunotherapeutics Ltd. entered into a license agreement granting a U.S. company exclusive rights to certain patents for development and commercialization, with an upfront fee due by December 15, 2024, and additional milestone payments and royalties on sales.

AI Assistant

SCINAI IMMUNOTHERAPEUTICS LTD

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.